M. Calamac, N. Stanic, O. Djurmez, M. Dimitrijević, J. Vukosavljević, K. Serovic, J. Oblakovic-Babic, I. Minić, I. Božović-Spasojević
{"title":"转移性HER-2阳性乳腺癌(MBC)放射完全缓解(rCR)后停止长期含曲妥珠单抗治疗安全吗?","authors":"M. Calamac, N. Stanic, O. Djurmez, M. Dimitrijević, J. Vukosavljević, K. Serovic, J. Oblakovic-Babic, I. Minić, I. Božović-Spasojević","doi":"10.1016/s0960-9776(23)00406-x","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":22301,"journal":{"name":"The Breast : Official Journal of the European Society of Mastology","volume":"39 2 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"P288 Is it safe to discontinue long-term trastuzumab containing therapy after radiological complete response (rCR) in metastatic HER-2 positive breast cancer (MBC)?\",\"authors\":\"M. Calamac, N. Stanic, O. Djurmez, M. Dimitrijević, J. Vukosavljević, K. Serovic, J. Oblakovic-Babic, I. Minić, I. Božović-Spasojević\",\"doi\":\"10.1016/s0960-9776(23)00406-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":22301,\"journal\":{\"name\":\"The Breast : Official Journal of the European Society of Mastology\",\"volume\":\"39 2 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Breast : Official Journal of the European Society of Mastology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s0960-9776(23)00406-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Breast : Official Journal of the European Society of Mastology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s0960-9776(23)00406-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
P288 Is it safe to discontinue long-term trastuzumab containing therapy after radiological complete response (rCR) in metastatic HER-2 positive breast cancer (MBC)?